KRAS inhibition drives adaptive surfaceome remodeling and reveals ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer
Jonathan M. DeLiberty, Fan Yi Kong, Qijia Yu, Nicole Sindoni, Johnson Lin, Kalisa Kang, Elizabeth Y. Kim, Sabrina Chen, Aparna Padhye, Oluwadara Coker, Joshua H. Choe, Joao A. Paulo, Myungsun Shin, Lewis Hendrianto, Kazuki Takahashi, , Joseph Douglas Mancias
This study identifies ALPP/ALPPL2 as a targetable vulnerability in pancreatic cancer by analyzing proteomic changes induced by KRAS inhibition and developing an antibody drug conjugate.
bioRxiv · Oct 2, 2026 · PreprintCancer Biology